http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 안지수 ( Jee Soo An ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
세포병리사의 업무량에 따른 적정인력 산정을 위한 업무실태 조사 연구
지수일 ( Soo Il Jee ),안용호 ( Yong Ho Ahn ),하화정 ( Hwa-jeong Ha ),강정은 ( Jeong Eun Kang ),원준호 ( Jun Ho Won ) 대한임상검사과학회 2021 대한임상검사과학회지(KJCLS) Vol.53 No.2
세포병리사는 인체를 구성하고 있는 세포의 상태를 분석하여 암을 포함한 다양한 질병을 진단하는 1차 선별자로서 역할을 수행하고 있으나, 세포병리사의 고용 형태, 업무량 등이 제대로 파악되고 있지 않다. 이에 본 연구는 세포병리사의 효율적인 직무 수행의 범위, 의료기관의 종별에 따른 세포병리사의 업무량 분석 결과를 토대로 병리과질관리 인증평가항목의 기준 설정에 기초자료를 제공하고자 하였다. 연구방법은 전국 의료기관에 근무하는 세포병리사 자격증 소지자를 연구대상으로 설문조사를 실시하였다. 총 245명의 세포병리사가 설문에 응답하였으며 그 중 1차 선별검사 업무를 수행하고 있는 인원은 178명(72.7%)으로 조사되었다. 각 기관별 1일 기준, 세포병리사 1인의 평균 1차 선별검사 건수는 대학병원그룹이 75.4장(16.8장/시간), 병원그룹이 72.4장(18.6장/시간) 그리고 76명이 응답한 전문수탁기관은 231장(32.6장/시간)으로 조사되었다. 이에 본 연구결과를 기초로 세포 선별검사 업무에 대한 기준지침을 수립하여 대한세포병리학회 등과 협의체를 구축하고, 현안 사항에 대한 해결방법을 모색하여 국민건강 보건 향상에 기여해야 할 것이다. Cytotechnologists evaluate and analyze disorders of cells that constitute the human body, and are involved in the primary assessment of diverse diseases, including cancer. However, the employment conditions and workload of cytotechnologists are poorly understood. This study was undertaken to provide basic data for establishing the criteria for quality control certification factors based on the scope of effective task performance of cytotechnologists, and to provide results of their workload analysis according to the type of medical institution. The study was conducted by enrolling certified cytotechnologists working at various nationwide medical institutions. Our analysis revealed that 178 personnel (72.7%) were involved in primary screening of samples. On an average, the daily number of primary screening of samples performed per cytotechnologist (76 respondents) was determined to be 75.4 chapters (16.8 chapters/hours) at the university hospital level, 72.4 chapters (18.6 chapters/hours) at the general hospital level, and 231 chapters (32.6 chapters/hours) at professional trust institutions. Our results indicate the necessity to establish a consultant with the Korean Cell Pathology Association, to enable finding solutions to solve existing issues by establishing accurate standard guidelines for assessing cell screening. Copyright Ⓒ 2021 The Korean Society for Clinical Laboratory Science. All rights reserved.
-
인체 모낭에서 TGF-β 발현에 대한 면역조직화학적 연구
원종현 ( Chong Hyun Won ),주영현 ( Young Hyun Joo ),이동훈 ( Dong Hun Lee ),안지수 ( Jee Soo An ),김범준 ( Beom Joon Kim ),권오상 ( Oh Sang Kwon ),조광현 ( Kwang Hyun Cho ),김규한 ( Kyu Han Kim ),은희철 ( Hee Chul Eun ) 대한피부과학회 2007 대한피부과학회지 Vol.45 No.4
Background: Although it is well known that transforming growth factor beta (TGF-β) may induce catagen change of hair follicles and inhibit hair growth, it is still unclear which subtype of TGF-β and its specified receptor might be expressed in human hair follicles of androgenetic alopecia (AGA) patients. Objective: To delineate precise expression of TGF-β subtype in human hair follicles of androgenetic alopecia patients. Methods: Immunohistochemical studies were performed on paraffin sections of human hair follicles by applying type 1, 2, and 3 TGF-β antibodies and type I and II receptor antibodies. We ascertained the expression of TGF-β subtype in hair follicles of androgenetic alopecia patients. We also compared the expression pattern of each type of TGF-β receptor. We evaluated the change of TGF-β expression of hair follicles in the catagen phase. Results: TGF-β1 was well-expressed in the outer area of the inner root sheath (IRS) or dermal connective sheath area. TGF-β2 was commonly expressed in the inner 1/2 of the outer root sheath (ORS). TGF-β3 was expressed in the hair cortex, IRS, and cuticle in normal hair follicles obtained from both the vertex and occipital area. On the contrary, in specimens from AGA, the enhanced expression of type 2 TGF-β or type II receptor was observed in the vertex area (bald) compared to the occipital area (non bald). When the expression patterns of TGF-β 1, 2, and 3 were compared between anagen and catagen phases, TGF-β2 and 3 were positively expressed in the epithelial strands and secondary hair germs in the catagen phase. The immunoreactivities of TGF-β 1 and 2 were intensified in the ORS areas of the catagen phase. Conclusion: The expression of type 1, 2 TGF-β and type I and II receptors in follicular epithelial cells might be related to catagen induction and development of androgenetic alopecia of human hair in vivo. (Korean J Dermatol 2007;45(4):321~326)
-
여성형 탈모에서 AP-FHG0604T의 유효성 및 안전성 평가에 관한 임상 연구
신효승 ( Hyo Seung Shin ),이승호 ( Seung Ho Lee ),김동현 ( Dong Hyun Kim ),안지수 ( Jee Soo An ),권오상 ( Oh Sang Kwon ),은희철 ( Hee Chul Eun ),김규한 ( Kyu Han Kim ) 대한피부과학회 2007 대한피부과학회지 Vol.45 No.2
Background: Hair loss is a very common disorder and the number of patients is known to be increasing. Female pattern hair loss (FPHL) is not only a medical problem but also a very severe psychosocial problem for many female patients. Anti-androgen drugs, mineral supplements and topical minoxidil have all been used for the treatment of FPHL. However they do not always achieve successful results and there is still much need for more effective therapy. Objective: The purpose of this 18-week, double-blind, placebo-controlled, randomized clinical trial was to investigate the efficacy and safety of a new topical agent, AP-FHG0604T, in the treatment of FPHL. Methods: A total of 33 women with FPHL (mean age: 33.4 years old) applied either a topical AP-FHG0604T solution (n=17), or placebo (vehicle for AP-FHG0604T solution; n=16) twice daily. Efficacy was evaluated by phototrichogram, investigator`s photographic and patient`s subjective assessments. All adverse effects were reported during the study. Results: After 18 weeks of therapy, topical AP-FHG0604T treatment showed a significant improvement compared to baseline values of total hair count, non-vellus hair count, and linear hair growth rate. In the placebo group, non-vellus hair count and ratio of anagen hair significantly decreased. The change rates of total hair count and non-vellus hair count in the AP-FHG0604T group were significantly higher than those in the placebo group. Neither investigator`s photographic assessments nor patient`s subjective assessments of hair growth showed statistically significant differences between the AP-FHG0604T group or the placebo group. Some patients who used AP-FHG0604T complained of local irritation during the study, but the irritation was so mild that they did not need any treatment for this. Conclusion: We conclude that AP-FHG0604T is a safe and efficient topical agent which can be used as another treatment of choice for FPHL, as shown by objective assessment with phototrichogram. (Korean J Dermatol 2007; 45(2):119~126)
ScienceON
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
